HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE

• DOI: 10.1016/j.htct.2021.10.1093
• Publication Date: 2021-11-07T19:09:01Z
• Authors: Nur OLGUN; Deniz KIZMAZOGLU; Batuhan OZDOGAR; Dilek INCE; Emre CECEN; Ceren KIZMAZOGLU; Şefika AKYOL; Ayşe DEMIRAL; Rıza CETINGOZ; Ayşe ONAL; Handan UCAR; Erdener OZER
• Keywords: Center (category theory); Single Center

To evaluate characteristics and treatment responses of patients with high grade gliomas (HGG) in our center. Medical files malignant CNS tumors between 1987-2020 were analyzed retrospectively. There 44 HGG. Diagnosis as follows: 21 pons glioma, 2 anaplastic astrocytoma, 11 ependimoma, 7 glioblastoma multiforme, 1 glioblastoma, gliomatosis cerebri. The median age at diagnosis was 6,5 yrs (7 – 17 yrs), M/F:25/19. Age distribution: <5 12 patients, 5-10 18 10-18 14 patients. most frequent complaints for gliomas: cranial nerve paralysis (52%), visual impairment (48%), headache (38%), power loss (43%) speech disorder (30%). Surgery performed to extrinsic component mass 3 gliomas.For other HGG: subtotal resection 16 gross total had performed.7 died before RT. And 37 received radiotherapy. RT doses varied 50-60 Gy.7 not chemotherapy, them chemo, others only For HGGs, platin based regimens used the first line treatment. Temozolamide, bevacizumab, irinotecan options. Median progression free survival time 6 mos (2weeks-25 mos) gliomas, mos(0 -74 mos).For Event rate 75%, one year 17%;one year, mos, two years overall rates 84%,52% 10%respectively.For HGGs: 57% 17% respectively. One 73% 36% High glioma is a group which still helplessness experienced Despite radiotherapy prognosis very poor. similar literature. With new developments molecular pathology, use target therapies, newly will improve.